This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barrington, R. E.
Right arrow Articles by Kohl, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barrington, R. E.
Right arrow Articles by Kohl, N. E.

 Previous Article  |  Next Article 

Mol. Cell. Biol., 01 1998, 85-92, Vol 18, No. 1
Copyright © 1998, American Society for Microbiology

A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis

RE Barrington, MA Subler, E Rands, CA Omer, PJ Miller, JE Hundley, SK Koester, DA Troyer, DJ Bearss, MW Conner, JB Gibbs, K Hamilton, KS Koblan, SD Mosser, TJ O'Neill, MD Schaber, ET Senderak, JJ Windle, A Oliff and NE Kohl
Department of Medicine, The University of Texas Health Science Center at San Antonio, 78284, USA.

The farnesyltransferase inhibitor L-744,832 selectively blocks the transformed phenotype of cultured cells expressing a mutated H-ras gene and induces dramatic regression of mammary and salivary carcinomas in mouse mammary tumor virus (MMTV)-v-Ha-ras transgenic mice. To better understand how the farnesyltransferase inhibitors might be used in the treatment of human tumors, we have further explored the mechanisms by which L-744,832 induces tumor regression in a variety of transgenic mouse tumor models. We assessed whether L-744,832 induces apoptosis or alterations in cell cycle distribution and found that the tumor regression in MMTV-v-Ha-ras mice could be attributed entirely to elevation of apoptosis levels. In contrast, treatment with doxorubicin, which induces apoptosis in many tumor types, had a minimal effect on apoptosis in these tumors and resulted in a less dramatic tumor response. To determine whether functional p53 is required for L-744,832- induced apoptosis and the resultant tumor regression, MMTV-v-Ha-ras mice were interbred with p53(-/-) mice. Tumors in ras/p53(-/-) mice treated with L-744,832 regressed as efficiently as MMTV-v-Ha-ras tumors, although this response was found to be mediated by both the induction of apoptosis and an increase in G1 with a corresponding decrease in the S-phase fraction. MMTV-v-Ha-ras mice were also interbred with MMTV-c-myc mice to determine whether ras/myc tumors, which possess high levels of spontaneous apoptosis, have the potential to regress through a further increase in apoptosis levels. The ras/myc tumors were found to respond nearly as efficiently to L-744,832 treatment as the MMTV-v-Ha-ras tumors, although no induction of apoptosis was observed. Rather, the tumor regression in the ras/myc mice was found to be mediated by a large reduction in the S-phase fraction. In contrast, treatment of transgenic mice harboring an activated MMTV-c-neu gene did not result in tumor regression. These results demonstrate that a farnesyltransferase inhibitor can induce regression of v-Ha-ras-bearing tumors by multiple mechanisms, including the activation of a suppressed apoptotic pathway, which is largely p53 independent, or by cell cycle alterations, depending upon the presence of various other oncogenic genetic alterations.


This article has been cited by other articles:

  • Toenjes, K. A., Stark, B. C., Brooks, K. M., Johnson, D. I. (2009). Inhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans. J Med Microbiol 58: 779-790 [Abstract] [Full Text]  
  • Marks, R. E., Ho, A. W., Robbel, C., Kuna, T., Berk, S., Gajewski, T. F. (2007). Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood 110: 1982-1988 [Abstract] [Full Text]  
  • Kamasani, U., Huang, M., DuHadaway, J. B., Prochownik, E. V., Donover, P. S., Prendergast, G. C. (2004). Cyclin B1 Is a Critical Target of RhoB in the Cell Suicide Program Triggered by Farnesyl Transferase Inhibition. Cancer Res. 64: 8389-8396 [Abstract] [Full Text]  
  • Manne, V., Lee, F. Y. F., Bol, D. K., Gullo-Brown, J., Fairchild, C. R., Lombardo, L. J., Smykla, R. A., Vite, G. D., Wen, M.-L. D., Yu, C., Wong, T. W., Hunt, J. T. (2004). Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models. Cancer Res. 64: 3974-3980 [Abstract] [Full Text]  
  • Bergo, M. O., Lieu, H. D., Gavino, B. J., Ambroziak, P., Otto, J. C., Casey, P. J., Walker, Q. M., Young, S. G. (2004). On the Physiological Importance of Endoproteolysis of CAAX Proteins: HEART-SPECIFIC RCE1 KNOCKOUT MICE DEVELOP A LETHAL CARDIOMYOPATHY. J. Biol. Chem. 279: 4729-4736 [Abstract] [Full Text]  
  • Sun, J., Ohkanda, J., Coppola, D., Yin, H., Kothare, M., Busciglio, B., Hamilton, A. D., Sebti, S. M. (2003). Geranylgeranyltransferase I Inhibitor GGTI-2154 Induces Breast Carcinoma Apoptosis and Tumor Regression in H-Ras Transgenic Mice. Cancer Res. 63: 8922-8929 [Abstract] [Full Text]  
  • Delmas, C., End, D., Rochaix, P., Favre, G., Toulas, C., Cohen-Jonathan, E. (2003). The Farnesyltransferase Inhibitor R115777 Reduces Hypoxia and Matrix Metalloproteinase 2 Expression in Human Glioma Xenograft. Clin. Cancer Res. 9: 6062-6068 [Abstract] [Full Text]  
  • Brunner, T. B., Hahn, S. M., Gupta, A. K., Muschel, R. J., McKenna, W. G., Bernhard, E. J. (2003). Farnesyltransferase Inhibitors: An Overview of the Results of Preclinical and Clinical Investigations. Cancer Res. 63: 5656-5668 [Abstract] [Full Text]  
  • Li, H. Y., Appelbaum, F. R., Willman, C. L., Zager, R. A., Banker, D. E. (2003). Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101: 3628-3634 [Abstract] [Full Text]  
  • Petit, T., Bearss, D. J., Troyer, D. A., Munoz, R. M., Windle, J. J. (2003). p53-independent Response to Cisplatin and Oxaliplatin in MMTV-ras Mouse Salivary Tumors. Molecular Cancer Therapeutics 2: 165-171 [Abstract] [Full Text]  
  • Arceci, R. J., Longley, B. J., Emanuel, P. D. (2002). Atypical Cellular Disorders. ASH Education Book 2002: 297-314 [Abstract] [Full Text]  
  • Rose, W. C., Lee, F. Y. F., Fairchild, C. R., Lynch, M., Monticello, T., Kramer, R. A., Manne, V. (2001). Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor. Cancer Res. 61: 7507-7517 [Abstract] [Full Text]  
  • Cohen-Jonathan, E., Evans, S. M., Koch, C. J., Muschel, R. J., McKenna, W. G., Wu, J., Bernhard, E. J. (2001). The Farnesyltransferase Inhibitor L744,832 Reduces Hypoxia in Tumors Expressing Activated H-ras. Cancer Res. 61: 2289-2293 [Abstract] [Full Text]  
  • Reichert, A., Heisterkamp, N., Daley, G. Q., Groffen, J. (2001). Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97: 1399-1403 [Abstract] [Full Text]  
  • Reuter, C. W. M., Morgan, M. A., Bergmann, L. (2000). Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 96: 1655-1669 [Abstract] [Full Text]  
  • Liu, A.-x., Du, W., Liu, J.-P., Jessell, T. M., Prendergast, G. C. (2000). RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors. Mol. Cell. Biol. 20: 6105-6113 [Abstract] [Full Text]  
  • Omer, C. A., Chen, Z., Diehl, R. E., Conner, M. W., Chen, H. Y., Trumbauer, M. E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M. T., Davide, J. P., Ellis, M. S., Gibbs, J. B., Greenberg, I., Hamilton, K., Koblan, K. S., Kral, A. M., Liu, D., Lobell, R. B., Miller, P. J., Mosser, S. D., O’Neill, T. J., Rands, E., Schaber, M. D., Senderak, E. T., Oliff, A., Kohl, N. E. (2000). Mouse Mammary Tumor Virus-Ki-rasB Transgenic Mice Develop Mammary Carcinomas That Can Be Growth-inhibited by a Farnesyl:Protein Transferase Inhibitor. Cancer Res. 60: 2680-2688 [Abstract] [Full Text]  
  • Law, B. K., Norgaard, P., Moses, H. L. (2000). Farnesyltransferase Inhibitor Induces Rapid Growth Arrest and Blocks p70s6k Activation by Multiple Stimuli. J. Biol. Chem. 275: 10796-10801 [Abstract] [Full Text]  
  • Lowe, S. W., Lin, A. W. (2000). Apoptosis in cancer. Carcinogenesis 21: 485-495 [Abstract] [Full Text]  
  • Emanuel, P. D., Snyder, R. C., Wiley, T., Gopurala, B., Castleberry, R. P. (2000). Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95: 639-645 [Abstract] [Full Text]  
  • Yang, W., Urano, J., Tamanoi, F. (2000). Protein Farnesylation Is Critical for Maintaining Normal Cell Morphology and Canavanine Resistance in Schizosaccharomyces pombe. J. Biol. Chem. 275: 429-438 [Abstract] [Full Text]  
  • Nielsen, L. L., Shi, B., Hajian, G., Yaremko, B., Lipari, P., Ferrari, E., Gurnani, M., Malkowski, M., Chen, J., Bishop, W. R., Liu, M. (1999). Combination Therapy with the Farnesyl Protein Transferase Inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in Preclinical Cancer Models. Cancer Res. 59: 5896-5901 [Abstract] [Full Text]  
  • Rowinsky, E. K., Windle, J. J., Von Hoff, D. D. (1999). Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development. JCO 17: 3631-3652 [Abstract] [Full Text]  
  • Du, W., Prendergast, G. C. (1999). Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors. Cancer Res. 59: 5492-5496 [Abstract] [Full Text]  
  • Mahgoub, N., Taylor, B. R., Gratiot, M., Kohl, N. E., Gibbs, J. B., Jacks, T., Shannon, K. M. (1999). In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor on Nf1-Deficient Hematopoietic Cells. Blood 94: 2469-2476 [Abstract] [Full Text]  
  • Del Villar, K., Urano, J., Guo, L., Tamanoi, F. (1999). A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors. J. Biol. Chem. 274: 27010-27017 [Abstract] [Full Text]  
  • Du, W., Liu, A., Prendergast, G. C. (1999). Activation of the PI3'K-AKT Pathway Masks the Proapoptotic Effects of Farnesyltransferase Inhibitors. Cancer Res. 59: 4208-4212 [Abstract] [Full Text]  
  • Wang, T.-H., Popp, D. M., Wang, H.-S., Saitoh, M., Mural, J. G., Henley, D. C., Ichijo, H., Wimalasena, J. (1999). Microtubule Dysfunction Induced by Paclitaxel Initiates Apoptosis through Both c-Jun N-terminal Kinase (JNK)-dependent and -Independent Pathways in Ovarian Cancer Cells. J. Biol. Chem. 274: 8208-8216 [Abstract] [Full Text]  
  • Du, W., Lebowitz, P. F., Prendergast, G. C. (1999). Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB. Mol. Cell. Biol. 19: 1831-1840 [Abstract] [Full Text]  
  • Law, B. K., Norgaard, P., Gnudi, L., Kahn, B. B., Poulson, H. S., Moses, H. L. (1999). Inhibition of DNA Synthesis by a Farnesyltransferase Inhibitor Involves Inhibition of the p70s6k Pathway. J. Biol. Chem. 274: 4743-4748 [Abstract] [Full Text]  
  • TAN, A., LEVREY, H., DAHM, C., POLUNOVSKY, V. A., RUBINS, J., BITTERMAN, P. B. (1999). Lovastatin Induces Fibroblast Apoptosis In Vitro and In Vivo . A Possible Therapy for Fibroproliferative Disorders. Am. J. Respir. Crit. Care Med. 159: 220-227 [Abstract] [Full Text]  
  • Norgaard, P., Law, B., Joseph, H., Page, D. L., Shyr, Y., Mays, D., Pietenpol, J. A., Kohl, N. E., Oliff, A., Coffey, R. J. Jr., Poulsen, H. S., Moses, H. L. (1999). Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) {{alpha}} and TGF{{alpha}}/neu Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis. Clin. Cancer Res. 5: 35-42 [Abstract] [Full Text]  
  • Suzuki, N., Urano, J., Tamanoi, F. (1998). Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA 95: 15356-15361 [Abstract] [Full Text]  
  • Pei, Z., Ghassemian, M., Kwak, C. M., McCourt, P., Schroeder, J. I. (1998). Role of Farnesyltransferase in ABA Regulation of Guard Cell Anion Channels and Plant Water Loss. Science 282: 287-290 [Abstract] [Full Text]  
  • Suzuki, N., Del Villar, K., Tamanoi, F. (1998). Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc. Natl. Acad. Sci. USA 95: 10499-10504 [Abstract] [Full Text]  
  • Okada, F., Rak, J. W., Croix, B. St., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., Kerbel, R. S. (1998). Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA 95: 3609-3614 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»